Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P06889 (Mol)
 630,302 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Auranofin (AF) is an orally active chrysotherapeutic agent used for the treatment of rheumatoid arthritis, a self-perpetuating inflammatory disease. Because of reports suggesting that AF and other gold complexes can, under certain circumstances, exacerbate rheumatoid inflammatory lesions in humans and adjuvant arthritic rats and that phospholipase C (PLC) and phospholipase A2 activities are increased in rheumatoid patients, the effects of AF and a related gold complex on in situ mammalian and purified Bacillus cereus PLC were examined. Results of our studies show that 1) AF and triethylphosphine gold chloride (TEPG), an AF analog, stimulated PLC activity in the sonicate of RAW 264.7 macrophages; 2) AF and TEPG stimulated B. cereus PLC activity in a concentration-dependent manner, but the pattern of stimulation and concentrations of drugs required to stimulate the purified enzyme differ from those seen with the macrophage PLC; 3) metals (cobalt and zinc) and sulfhydryl reagents (N-ethylmaleimide, iodoacetic acid, and glutathione), tested at the same concentrations of AF that enhanced PLC activity, had no effect on the enzyme. These data suggest that stimulation of PLC may be a generic phenomenon since two divergent PLCs are affected by gold complexes. Additionally, these studies may provide one potential explanation for rheumatoid lesion flares seen in patients and animals on chrysotherapy.
Mol Pharmacol 1987 Sep
PMID:Effect of auranofin and other gold complexes on the activity of phospholipase C. 311 79

Epidermal growth factor (EGF) directly enhanced luteinizing hormone (LH) release from dispersed rat pituitary cells in monolayer cultures as well as in superfusion columns. This 2.3-fold stimulatory effect was dose and time dependent and was also reconfirmed in a superfusion system. Retinal, a protein kinase C inhibitor, counteracted the EGF effect only partially. Further experiments were therefore carried out to investigate alternate EGF mechanisms. Nordihydroguaiaretic acid and chloroquine suppressed the stimulatory effect of EGF in a dose-dependent manner. Moreover, EGF (10(-7) M) stimulated [3H]arachidonate release from pre-labelled rat pituitary cells. This indicates that phospholipase A2 and arachidonic acid may be involved in EGF action on LH release from rat pituicytes.
Mol Cell Endocrinol 1988 May
PMID:Epidermal growth factor stimulates luteinizing hormone and arachidonic acid release in rat pituitary cells. 326 Aug 75

Modification of Trimeresurus flavoviridis phospholipase A2 with a 5-fold molar excess of tetranitromethane produced 40% active mononitrotyrosyl phospholipase A2 in which Tyr-76 was specifically nitrated. This is in contrast to the case of mammalian pancreatic phospholipases A2 where Tyr-70 but not Tyr-76 was nitrated. When Ca2+ was bound to T. flavoviridis mononitrotyrosyl phospholipase A2, nitrated tyrosine (Tyr(NO2))-76 moved from a less polar site to a polar site with the decrease of the pKa value of its hydroxyl group. Nitration of Tyr-76 did not influence the binding affinity to Ca2+. Addition of laurylphosphorylcholine to mononitrotyrosyl phospholipase A2 in the presence of Ca2+ caused the movement of Tyr(NO2)-76 from a polar environment to a less polar environment with the rise in the pKa value. Tyrosine-76 is located in the site whose environmental polarity is affected by the binding of the ligands to the active site. As Tyr-76 is located in the site not proximal to the active site, it could be assumed that the conformational change induced by the binding of the ligands extends to the region remote from the active site in T. flavoviridis phospholipase A2. This might provide evidence of long-range diffusional coupling between remote sites in the noncooperative globular protein.
J Mol Recognit 1988 Jun
PMID:Transition of environmental polarity of tyrosine-76 of Trimeresurus flavoviridis phospholipase A2 upon active site ligand binding. 327 23

Bovine pancreatic phospholipase A2 covalently inhibited by p-bromo-phenacyl-bromide was crystallized from 50% (v/v) 2-methyl-2,4-pentanediol. The space group was P3(1)21 with cell dimensions a = b = 46.73 A and c = 102.5 A (1 A = 0.1 nm). Diffraction data were collected by oscillation photography from one single crystal of dimensions 0.2 mm x 0.2 mm x 0.2 mm. The crystal structure was determined to a resolution of 2.5 A by crystallographic refinement of a starting model, which consisted of native bovine pancreatic phospholipase A2 positioned and oriented in the P3(1)21 cell as in the bovine pro-phospholipase A2. The crystallographic R-factor decreased from 0.378 to 0.197 after 70 refinement cycles. For the greater part the three-dimensional structure was very similar to that of native phospholipase. The inhibitor group shows up clearly. However, as in solution, there is no calcium ion bound any more in the active site, and this causes a significant conformational change in the loop from residue 59 to 73. This loop is remote from the calcium binding site. Interestingly, this is the same loop that also shows different conformations in other phospholipase A2 molecules. The inhibitor molecule has hydrophobic interactions with Phe5 and Cys45. Rational design of specific and potent inhibitors of phospholipase A2 catalysis is discussed on the basis of the present three-dimensional structure.
J Mol Biol 1988 Mar 05
PMID:Crystal structure of bovine pancreatic phospholipase A2 covalently inhibited by p-bromo-phenacyl-bromide. 337 39

Trichloroethylene (TCE) is a common organic solvent in use as a dry cleaning agent as well as an inhalant anesthetic. Nevertheless the effects of this material on the pulmonary surfactant which prevents alveolar collapse at maximal expiration is not known. Therefore, we have examined the effect of TCE on the intra- and extracellular surfactant pools and the activity of phospholipase A2, an enzyme which controls the remodeling of phosphatidylcholine to dipalmitoylphosphatidylcholine, the primary constituent of the pulmonary surfactant. Male CD-1 mice were treated ip with 2500 or 3000 mg/kg TCE. Twenty-four hours later mice were anesthetized and the lungs lavaged. Mice were then killed, the lungs perfused and excised, and subcellular fractions including lamellar bodies prepared. Some lungs were prepared for ultrastructural examination. Phospholipase A2 was assayed in all subcellular fractions. Phospholipid was assayed in the lavage (extracellular surfactant) and the lamellar bodies (intracellular surfactant). TCE (2500 mg/kg) caused selective exfoliation of Clara cells. However, only the dose of 3000 mg/kg TCE produced a significant decrease in the intracellular surfactant phospholipid. Minimal changes occurred in the phospholipid profiles. Phospholipase A2 specific activity was significantly decreased at both dosages within the lung microsomal fraction. In addition after treatment with 3000 mg/kg TCE the enzyme activity in the lamellar body fraction was significantly increased. These data suggest that inhalation of TCE may damage the enzymes which are responsible for synthesizing the pulmonary surfactant resulting in lower amounts of surfactant being stored and available for secretion into the alveolus.
Exp Mol Pathol 1988 Aug
PMID:Pulmonary toxicity of trichloroethylene: induction of changes in surfactant phospholipids and phospholipase A2 activity in the mouse lung. 339 65

Amiodarone is used extensively for the chronic treatment of life-threatening arrhythmias caused by ischemic heart disease. However, chronic therapy with this agent results in phospholipidosis in various tissues and it has been suggested that the inhibition of lysosomal phospholipase A by this drug contributes to this abnormality. Exogenous amiodarone has been shown to inhibit purified rat liver lysosomal phospholipase A1, as well as acid phospholipase activities of alveolar macrophage homogenates and those of snake venom phospholipase A2 and bacterial phospholipase C. The effects of drug treatment on heart have not been explored. The results described here demonstrate that amiodarone also significantly increases (37%, p less than 0.001) phospholipid content in cat hearts. This increase is proportionately distributed to all major phospholipid classes, with the exception of sphingomyelin which appears to increase more than the others. In addition, the data also show that following amiodarone treatment, the endogenous drug levels in the heart were sufficient to reduce in vitro losses of membrane phospholipid at 37 degrees C by inhibiting a variety of endogenous phospholipases at physiological (7.4), ischemic (6.2) and acidic (5.0) pH values. This protection is more pronounced at acidic pH values than at physiological pH. Endogenous amiodarone also affects myocardial phospholipase activities towards exogenous phosphatidylcholine and again the extent of inhibition is more at acidic pH. These results suggest that amiodarone induces phospholipidosis in the heart by inhibiting phospholipid catabolism and that its antiarrhythmic properties may reside in its ability to modulate alkaline, neutral and acid phospholipase activities in ischemia. To what extent amiodarone metabolites (desethylamiodarone and bis-desethylamiodarone) are involved in these actions remains to be determined.
Mol Cell Biochem 1987 Nov
PMID:Effects of chronic amiodarone treatment on cat myocardial phospholipid content and on in vitro phospholipid catabolism. 345 65

Effects of phospholipase A2 (PLA2)-catalyzed hydrolysis of sarcolemmal phospholipids on ventricular muscarinic receptors were examined by measuring specific binding of 3H-quinuclidinyl benzilate (3H-QNB) to purified canine sarcolemmal vesicles. Scatchard analysis of 3H-QNB saturation isotherms (25 degrees C, pH 7.4) yielded a dissociation constant (Kd) of 58 +/- 10 pM and maximal binding capacity (Bmax) of 5.7 +/- 1.3 pmol/mg. Pretreatment of the sarcolemmal membranes with PLA2 (1 U/ml) for 5 and 30 mins reduced Bmax to 38% and 7% of control, and increased Kd to 109 +/- 21 and 129 +/- 12 pM, respectively. Washing of PLA2-treated sarcolemmal vesicles with defatted albumin resulted in a partial recovery of Bmax, presumably by removing hydrolysis products. PLA2 also reduced equilibrium binding of 3H-QNB to 43% of control when reactions were started by simultaneous addition of 3H-QNB and 1 U/ml PLA2; however, under these conditions the inhibitory effect of PLA2 could be overcome by increasing 3H-QNB from 30 to 600 pM. PLA2 added at equilibrium (59 mins after reaction start) had no effect on 3H-QNB binding. Lipid hydrolysis by PLA2 was unaffected by the presence of bound 3H-QNB. The ability of ligand occupation and removal of hydrolysis products to attenuate the effects of PLA2-treatment on muscarinic receptor sites may be explained if modification of the membrane lipid bilayer leads to transitions between different states of the receptor.
J Mol Cell Cardiol 1987 Jun
PMID:Effect of exogenous phospholipase A2 treatment on cardiac muscarinic receptors of highly purified canine sarcolemmal vesicles. 362 86

Many experimental observations show that prolonged physical exercise produces an increase of muscular glucose uptake. Recent findings suggest that the kallikrein-kinin-prostaglandin system may be related to this phenomenon, but so far, no direct evidence of quantitative alteration in this system has been observed during exercise. We measured plasma kallikrein and muscular phospholipase A2 activity, respectively the first and the last steps of reactions leading to prostaglandin synthesis. We demonstrated, for the first time, that during exercise plasma kallikrein activity increases in rats. We also observed an increase of muscular phospholipase A2 activity after exercise and a positive correlation between these parameters. Our findings demonstrate, under physiological conditions of enhanced muscular glucose uptake, a concomitant significant increase of plasma kallikrein and muscular phospholipase A2 activity, supporting the hypothesis that activation of the kallikrein-kinin-prostaglandin system may play some part in the enhanced muscular glucose uptake during physical activity.
Mol Cell Endocrinol 1986 Apr
PMID:Effect of exercise on plasma kallikrein and muscular phospholipase A2 activity in rats. 363 29

Liver and soleus muscles of control animals and rats recovering from a single hindlimb scald were analyzed for diphosphatidyl glycerol, phosphatidyl ethanolamine, phosphatidyl choline, sphingomyelin, lysophosphatidyl choline, phosphatidyl inositol, and phosphatidyl serine. Liver of 4-hr postburn rats exhibited decreased contents of diphosphatidyl glycerol (-20%), phosphatidyl ethanolamine (-11%), and phosphatidyl choline (-7%). At 3 days after the burn, only an 11% decrease in hepatic phosphatidyl inositol was observed. Soleus muscle of the unburned limb of burned rats showed at 3 days postburn an 11% decrease in sphingomyelin content but the other measured phospholipids were at control level. In contrast, soleus muscle from the contralateral burned limb exhibited increased contents of sphingomyelin (+29%), lysophosphatidyl choline (+145%), and phosphatidyl serine (+27%) compared to control uninjured animals. It also showed a 25% higher phosphatidyl inositol level than the contralateral uninjured counterpart. It is concluded that recovery from a single hindlimb scald is associated with alterations in phospholipid metabolism in the liver and in the region of the wound. The local response to thermal injury may be mediated, in part, by stimulated activity of phospholipase A2.
Exp Mol Pathol 1986 Oct
PMID:Hepatic and skeletal muscle phospholipid metabolism in recovering burned rats. 377 Jan 44

We studied the in vitro responsiveness of prolactin-secreting MtTW15 and 7315a pituitary tumor cells to stimulation by selected secretagogues using a perifusion technique. Prolactin release by these cells was refractory to thyrotropin-releasing hormone (TRH) and vasoactive intestinal peptide (VIP). In contrast, 50 mM K+, dibutyryl cAMP, theophylline, phospholipase A2 and phorbol myristate acetate all increased prolactin release from both tumor cell types. Phospholipase C increased prolactin release from 7315a but not from MtTW15 cells. TRH increased 32P incorporation into phosphatidylinositol in the 7315a but not in the MtTW15 tumor cells. Therefore, the refractoriness of these tumors to TRH and VIP may be at least partially due to a defect in the receptor or in the process that couples receptor binding and intracellular biochemical processes. In the MtTW15 tumor at least part of the defect may be related to phospholipid hydrolysis.
Mol Cell Endocrinol 1984 Jul
PMID:Prolactin release from MtTW15 and 7315a pituitary tumors is refractory to TRH and VIP stimulation. 608 25


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>